Biphenotypic acute leukaemia: A case series

Ahmed Aribi, Carlos Bueso-Ramos, Eli Estey, Zeev Estrov, Susan O'Brien, Francis Giles, Stefan Faderl, Deborah Thomas, Partow Kebriaei, Guillermo Garcia-Manero, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

Original languageEnglish (US)
Pages (from-to)213-216
Number of pages4
JournalBritish Journal of Haematology
Issue number2
StatePublished - Jul 2007


  • Biphenotypic acute leukaemia
  • Diagnosis
  • Immnuophenotype
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Biphenotypic acute leukaemia: A case series'. Together they form a unique fingerprint.

Cite this